Cybin receives IND authorization from the FDA to study ketamine's psychedelic effect on the cerebral cortex.
Cybin receives IND authorization from the FDA to study ketamine's psychedelic effect on the cerebral cortex.
Levitee Labs announces new credit facility for up to CAD$12 million to finance expansion of its clinics network.
The UK drug regulator (MHRS) has granted Small Pharma Fast-Track Designation with respect to SPL026 for Major Depressive Disorder (MDD).
Numinus prepares for a Phase I clinical trial of its proprietary psilocybin extract.
Small Pharma announces receiving DTC Eligibility and its OTCQB listing to broaden liquidity and increase access for U.S. investors.
Cybin has completed its 74th pre-clinical study and anticipates commencing human clinical studies in early 2022.
Compass Pathway's fourth U.S. patent covers its Form A hydrate psilocybin, and is the first patent for this formulation.
Field Trip is adding three new clinics to its network, with two of the three already open and the third opening imminently.
Small Pharma commences enrolling patients for its Phase IIa DMT-based clinical trial aimed at treating Major Depressive Disorder.
Levitee Labs announces a partnership with Adracare Inc., a subsidiary of Well Health Technologies (WELL), to build out a digital therapeutics platform.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now